Matinas BioPharma (MTNB) just unveiled an announcement.
Matinas BioPharma Holdings, Inc. has shared promising updates on its Compassionate/Expanded Use Access Program involving MAT2203, an oral antifungal treatment. Patients who previously faced renal toxicity from AmBisome® saw significant renal function improvements after switching to MAT2203, with many experiencing full or partial recovery from various severe infections. The program, which includes 19 patients from notable healthcare institutions, is showing encouraging results, with complete resolution for those who completed their treatment and continued improvements in others. These findings highlight MAT2203’s potential as a safer alternative for patients with limited options due to drug resistance or intolerance.
See more insights into MTNB stock on TipRanks’ Stock Analysis page.
